and Gene Polymorphisms in a Thai Population.

Introduction: Genetic polymorphisms of drug transporters influence drug transporter activity and alter pharmacokinetic profiles of the drugs. Organic anion transporting polypeptide 1B1 (OATP1B1) and breast cancer resistance protein (BCRP) are important transporters encoded by solute carrier organic anion transporter family member 1B1 () gene and ATP-binding cassette subfamily G member 2 () gene, respectively. Polymorphisms in these genes are associated with increased plasma statins concentrations, statin-induced myopathy and poor response to allopurinol treatment.

Purpose: We explored allele and genotype frequencies of S and genes including their predicted phenotypes in 53 Thai participants. Of these, 17 had chronic kidney disease and were on statins.

Materials And Methods: Genotyping analysis for c.521T>C (rs4149056), c.388A>G (rs2306283), g.-11187G>A (rs4149015), and c.421C>A (rs2231142) was done by using TaqMan Real time PCR. All were tested for Hardy-Weinberg Equilibrium.

Results: Most of the participants (80%) had normal function haplotypes ( and ) while decreased ( and ) and unknown () function haplotypes were less observed. Four phenotypes of were observed: 69.81% had normal function (,, and ), 13.21% had intermediate function (, and ), 9.43% had indeterminate function ( and ) and 7.55% had low function ( and ). c.421A allele frequency was 25%. The frequency of c.421CA and AA phenotypes were 37.7% and 5.7%, respectively. The allele and genotype frequencies observed are consistent with reports in Asians. However, there were differences in major allele distributions between Asians and Caucasians for c.388A>G; c.388G were highly found in Asians, but c.388A were more observed in Caucasians.

Conclusion: This study showed that in the Thai population, there were 4 SNPs of and genes. This finding may be clinically applied to minimize inter-individual variability of drugs such as statins and allopurinol. Further study with a larger sample size is needed to assess the drug profiles and responses to treatment.